Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 850 of 2529 entries
View as:

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Phase: N/A Priority: Normal
NCT ID: NCT04353492 Org: User:
Start: 07/14/20 End: 03/11/25 Due: 03/11/26

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Phase: N/A Priority: Normal
NCT ID: NCT06997588 Org: User:
Start: 10/21/25 End: 09/30/30 Due: 09/30/31

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Phase: N/A Priority: Normal
NCT ID: NCT04539041 Org: User:
Start: 02/16/21 End: 10/17/24 Due: 10/17/25

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT01355614 Org: User:
Start: 06/30/11 End: 03/31/13 Due: 03/31/14

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Phase: N/A Priority: Normal
NCT ID: NCT05959304 Org: User:
Start: 10/04/24 End: 02/28/26 Due: 02/28/27

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Phase: N/A Priority: Normal
NCT ID: NCT02150213 Org: User:
Start: 08/31/14 End: 09/30/15 Due: 09/30/16

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00426556 Org: User:
Start: 07/31/07 End: 03/31/14 Due: 03/31/15

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02807844 Org: User:
Start: 06/29/16 End: 06/04/20 Due: 06/04/21

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Phase: N/A Priority: Normal
NCT ID: NCT02966353 Org: User:
Start: 03/31/17 End: 02/15/19 Due: 02/15/20

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Phase: N/A Priority: Normal
NCT ID: NCT01082367 Org: User:
Start: 04/30/10 End: 06/30/15 Due: 06/30/16

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Phase: N/A Priority: Normal
NCT ID: NCT02939599 Org: User:
Start: 02/01/18 End: 11/06/18 Due: 11/06/19

Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00405652 Org: User:
Start: 01/31/07 End: 09/30/08 Due: 09/30/09

Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels

Phase: N/A Priority: Normal
NCT ID: NCT00154193 Org: User:
Start: 06/30/04 End: - Due: -

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00456833 Org: User:
Start: 06/30/05 End: - Due: -

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT03927690 Org: User:
Start: 05/24/19 End: 08/31/22 Due: 08/31/23

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03111992 Org: User:
Start: 12/18/17 End: 03/02/20 Due: 03/02/21

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT00644878 Org: User:
Start: 10/31/08 End: 03/31/12 Due: 03/31/13

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT01433263 Org: User:
Start: 08/31/11 End: 04/30/14 Due: 04/30/15

Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT00968591 Org: User:
Start: 11/30/09 End: - Due: -

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

Phase: N/A Priority: Normal
NCT ID: NCT04300296 Org: User:
Start: 07/27/20 End: 05/03/22 Due: 05/03/23

LATAM LOWERS LDL-C

Phase: N/A Priority: Normal
NCT ID: NCT06501443 Org: User:
Start: 02/11/25 End: 11/29/26 Due: 11/29/27

Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00378014 Org: User:
Start: 08/31/06 End: 01/31/13 Due: 01/31/14

Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT01982292 Org: User:
Start: 05/31/14 End: 09/30/15 Due: 09/30/16

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01625377 Org: User:
Start: 12/31/12 End: 03/31/15 Due: 03/31/16

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05397496 Org: User:
Start: 10/03/22 End: 06/05/28 Due: 06/05/29